Notice ID: 0180db43bc954eb4a3ee8372c1c2c9cbSpecial Notice
PANDHA-26-P-0000 046638 Defibrinated Rabbit Blood
Responses closed . Full description on SAM.gov.
Description
The Defense Health Agency Contracting Activity (DHACA) on behalf of the Walter Reed Army Institute of Research (WRAIR), intends to negotiate on a sole source basis in accordance with FAR 6.302 with vendor Lampire Biological Labs, Inc., 3599 Farm School Rd, Ottsville, PA 18942-1536
The contractor shall supply 48 units (50ml per bottle equals one unit) of defibrinated rabbit blood per period of performance, base year plus four (one-year) option periods. Each unit shall have a lot number and associated product data sheet. Product shall be packaged to protect from damage during shipping, prevent leaks or spillage, comply with appropriate shipping regulations, and maintain temperature of 2-8 degrees Celsius upon arrival at destination.
Overview
Agency:
Department of WarDEFENSE HEALTH AGENCY (DHA)
Office:Not specified
Posted:October 8, 2026
NAICS:325414: Biological Product (except Diagnostic) Manufacturing
Last Updated:Oct 20, 2026
First published:
Last updated on SAM.gov:
PSC:6550: IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS
Set-Aside:No Set aside used
Type:Special Notice
Place of Performance:Silver Spring, Maryland, 20910
Award Overview
Possible prior contracts
Sign in to see possible prior contracts for this requirement (matched by agency, NAICS and place of performance; not confirmed).
Contacts
Contracting Officer
Primary Contact
Linda Hinson
Secondary Contact
Lance Nowell
Documents
Files (1)
- Download
B01. Notice of Intent to Sole Source PANDHA-26-P-0000 046638.pdf
98 KBAdded in Special Notice version 1Posted
Lifecycle
- 1Version 1Special NoticeCurrent
PANDHA-26-P-0000 046638 Defibrinated Rabbit Blood
Similar Opportunities
Title | Phase | Agency | NAICS | Set Aside | Posted | Deadline | Location |
|---|---|---|---|---|---|---|---|
See Soliciation Amendment 0001. USAISR's Combat Casualty Care Research Team 1 (CRT-1) requires resupply of its Blood Donor Room on a reoccurring basis in order to satisfy research requirements for blood collection. USAISR currently has three Terumo Trima Accel Blood Collection Systems in operation. These units support numerous research protocols. Various collection sets are used to collect a variety of blood products from donors. The Trima instrument is FDA-approved, but only with the use of original manufacturer-supplied consumable products. These consumables are specific to the instrument and there are no generic substitute products available in the marketplace. Please note - This is a 100% ser-aside for Service-Disabled Veteran-Owned Small Businesses. See attached complete solicitation for all requirement details and instructions to offerors. | Solicitation | 325413 | Service-Disabled Veteran-Owned Small Business Set-Aside | 10/19/2026 | 10/29/2026 | 0, TX | |
The attached document is the Redacted Justification and Approval for the Other than Full anbd Open Competition of theSequencing System for HIV-1 Testing for WRAIR. | Sole Source / J&A | 325413 | No Set-Aside | 10/01/2026 | Open | Silver Spring, MD | |
DLA – TS E&A, in conjunction with the United States Army Medical Materiel Center-Europe (USAMMCE), is conducting market research to support the recompete of its commercial laboratory supplies contract. The resulting contract will provide clinical laboratory reagents, test cartridges, calibrators, controls, and associated consumables that operate in conjunction with specific Government-owned laboratory analyzers and capital equipment (e.g., Abbott i-STAT, Siemens DCA 2000, and other point-of-care or automated platforms). The primary ordering activity and logistics hub is USAMMCE, servicing Department of Defense (DoD) medical treatment facilities and operational forces across the European Command (EUCOM) and possibly Central Command (CENTCOM) theaters. The follow-on ordering period is projected to commence on 15 January 2028. | Market Research | 325413 | No Set-Aside | 10/01/2026 | 10/30/2026 | Kaiserslautern, DE-RP | |
The Defense Health Agency (DHA) Contracting Activity (DHACA), on behalf of the DHA’s Portfolio Acquisition Executive Medical Products (PAE MP), intends to issue a firm-fixed price Indefinite Delivery/Indefinite Quantity contract on a sole source basis under the authority of the Revolutionary Federal Acquisition Regulation (FAR) Overhaul, FAR 6.103-1, only one responsible source and no other supplies or services will satisfy agency requirements, to Vascular Solutions LLC, 6420 Sycamore Ct N, Maple Grove, Minnesota 55369-6032. Vascular Solutions, LLC is the only source able to meet the Government’s requirements. The Government has a has a critical requirement for supply of a Food and Drug Administration (FDA) approved Freeze Dried Plasma (FDP) product for transfusion when plasma is required and other plasma products are not available. The FDA approved Vascular Solutions, LLC FDP product, EZPLAZ™, on 29 July 2026. Vascular Solutions LLC holds the first and only FDA-approved (licensed) FPD product on the market. This Notice of Intent is not a request for competitive proposals and no solicitation document exists for the requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to perform the required work. Responses must be supported with clear and convincing evidence articulating the ability to provide FDA approved FDP product. Capability statements shall not exceed 5 (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source contract. If no written responses are received by the date listed below, an Indefinite Delivery/Indefinite Quantity contract will be awarded without further remark. Capability statements are due by 3:00 PM local time, 16 September 2026. Capability statements shall be submitted by e-mail ONLY as a Microsoft Word or Adobe PDF attachment to the following address: timothy.j.kelly169.civ@health.mil and shannon.p.lertora.civ@health.mil. | Special Notice | 325412 | No Set-Aside | 09/01/2026 | 09/16/2026 | - | |
Notice of Intent (NOI) to Sole Source Title: Vela Sentosa SQ Next Generation Sequencing (NGS) for FDA Approved HIV-1 Genotype Sequencing Requiring Activity: Walter Reed Army Institute of Research (WRAIR) , Diagnostics and Countermeasures Branch (DCB) Related Notice: HT9426-26-RFI-5892 Product Service Code (PSC): 6550 - In Vitro Diagnostic Substances, Reagents, Test Kits and Sets North American Industry Classification System (NAICS) Code: 325413 - In-Vitro Diagnostic Substance Manufacturing Small Business Size Standard: 1250 employees The Defense Health Agency Contracting Activity (DHACA) on behalf of the Diagnostics and Countermeasures Branch (DCB) at the Walter Reed Army Institute of Research (WRAIR) intends to award a Firm Fixed Price contract on a sole source basis to Vela Diagnostics, USA INC; 353C US Highway 46; STE 250; Fairfield, New Jersey 07004; Cage Code 86YT5 under the RFO FAR 6.103-1 – Only one responsible source can supply the required products, and no other type of supplies or services will satisfy requirements. Description of Services: Via a reagent rental agreement, the contractor shall provide all Sentosa sequencer kits, consumables, supplies, sequencing systems and sub-components, and maintenance and repair. The HIV Diagnostics and Reference Lab (HDRL), DCB at the WRAIR currently utilizes the Sentosa SQ Next Generation Sequencing (NGS) system in order to perform HIV genotype testing which is critical for the monitoring of drug resistance mutations in HIV-1 infected soldiers and their beneficiaries. The Sentosa NGS system includes instrumentation and reagents required to perform the Vela Sentosa SQ HIV-1 Genotype test in a College of American Pathologist (CAP) accredited laboratory. As the system and assay is Food and Drug Administration (FDA) approved, clinical testing laboratories are required to use the instruments and reagents approved by the FDA in the execution of the test. Market Research was conducted and indicated similar products from other companies cannot meet or be modified to meet the Government’s requirements. Additionally, this contract requires a reagent rental agreement between the manufacturer and the Government. Vela has confirmed that authorized third party vendors of Vela products are not authorized to offer this agreement; ergo, the requirements of this contract can only be met by Vela. This special notice of intent is not a request for competitive proposals, and no solicitation document exists for this requirement. Meaningful submissions received in response to this notice will be considered solely for the purpose of determining whether a competitive procurement is in the best interest of the Government. If no meaningful, written submissions are received by the date listed below, after the publication of this notice, the solicitation will be issued as a sole source requirement to Vela Diagnostics, USA INC. Based on the above information, the only technically acceptable vendor to fulfill this requirement is Vela Diagnostics, USA INC. Submit capability statements (using PDF, MS Word, or Excel attachments) to Ms. Brenda Mena at e-mail: brenda.i.mena.civ@health.mil. Capability statements are due no later than 10:00am Eastern Daylight Time on 27 August 2026. No phone calls will be accepted | Special Notice | 325413 | No Set-Aside | 08/12/2026 | 08/27/2026 | Silver Spring, MD |
Additional Details
Solicitation Number
PANDHA-26-P-0000_046638
Archive Date
Nov 7, 2026